

Identifying Post-Vaccination Complications and Their Causes: An Analysis of COVID-19 Patient Data

American Frontline Doctors Issue Brief for Citizens, Policymakers and Physicians

By Dain Pascocello Global Research, April 30, 2021 America's Frontline Doctors 26 April 2021 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles **can be read in 51 languages by activating the "Translate Website"** drop down menu on the top banner of our home page (Desktop version).

Statement of Position

After several months dealing with capacity-related issues in COVID-19 vaccine administration, US states are set to find themselves with a supply of Pfizer, Moderna, and Johnson & Johnson immunizations outstripping demand for the experimental shots.

According to a recent <u>report</u> by the Kaiser Family Foundation, by about mid-May states will reach a "tipping point where demand for rather than supply of vaccines is our primary challenge."

One official with the American Public Health Association <u>put it this way</u>: "Anybody who's ever done a public health program knows that the last 20-30% of your target is the hardest." Perhaps anticipating the challenge, the Biden administration dedicated <u>\$48 billion</u> in its stimulus legislation to "implement a national, evidence-based strategy for testing, contact tracing, surveillance, and mitigation with respect to SARS-CoV-2 and COVID-19."

By means of comparison, the <u>National Intelligence Program</u> budget, which includes the CIA and parts of the FBI, will spend about \$62 billion in the current year – just 29% more than a single COVID-related line item in the president's "American Rescue Plan."

On April 24, state health authorities in Indiana, New York, Virginia, Missouri, and Michigan <u>resumed</u> administering Johnson & Johnson's COVID vaccine following an 11-day federal "pause" on the single-shot inoculation. According to published <u>reports</u>, a review by the Centers for Disease Control and Prevention's (CDC) advisory committee, known as ACIP, uncovered 15 cases of vaccine side effects involving potentially fatal blood clots. All were women, most under 50 years old. Three died and seven remain hospitalized. ACIP ultimately decided to lift the pause and recommended attaching a warning label to the experimental injection, to which J&J's chief medical officer<u>agreed</u> to add at a later date.

The CDC's early warning system for vaccine side effects, its 30-year-old <u>Vaccine Adverse</u> <u>Event Reporting System</u>, or VAERS, has captured <u>thousands</u> of other "adverse events" since the COVID-19 vaccination effort began in late 2020. Yet these complications have received a fraction of the attention paid to J&J's blood-clotting controversy. Why? America's Frontline Doctors (AFLDS) opposes attempts by state and federal jurisdictions to mandate vaccination for COVID-19 and supports further study by independent health officials before the Food and Drug Administration (FDA) replaces its conditional "emergency use authorization" (EUA) for the immunizations with full approval, known as a biologics license, a decision which could come as early as April or May 2021. This AFLDS Issue Brief is intended to provide additional information for concerned citizens, health experts, and policymakers about adverse events and other post-vaccination issues resulting from the three experimental COVID-19 vaccines currently administered under EUA. As always, potential vaccine recipients should weigh the available evidence on medical side effects against their particular needs free of third-party coercion, intimidation, and threats.

Taking Patient Experiences Seriously

Drugmaker Pfizer expects to collect <u>\$15 billion</u> in 2021 from sales of its mRNA experimental COVID vaccine. There is an irrepressible economic incentive among pharmaceutical companies for <u>childhood COVID vaccines</u>, <u>boosters</u>, and the like. Public health experts should stop and assess data on possible vaccine side effects and related post-vaccination questions before it is too late. Here are some major categories of concern as-yet publicly unaddressed by either the FDA or CDC. AFLDS believes these patient concerns ought to be taken more seriously by health regulators in the United States and abroad. Failing to consider these and other "known unknowns" is a dereliction of basic medical research.

1. Why is there concern surrounding this particular vaccine?

The COVID-19 vaccines are still experimental. They are currently being used on an "emergency" basis and are not FDA approved. It takes years to be sure something new is safe. The vaccines are new as is the technology they employ. **This new biotechnology introduces something called a "spike protein" instead of the traditional attenuated antigen response in a conventional vaccine. No one knows definitively the long-term health implications for the body and brain, especially among the young, related to this spike protein. In addition, if documented problems with the protein do arise, there will never be any way to reverse the adverse effects in those already vaccinated.**

2. What about the reported neurological issues?

There are two major neurological concerns related to the COVID vaccines. These are the spike proteins and the lipid nanoparticles which carry the mRNA into the cell. They are both capable of <u>passing through</u> the "<u>blood-brain barrier</u>" which typically keeps the brain and spinal cord completely insulated from entrants into the body. There simply has not been enough time to know what brain problems and how often a brain problem will develop from that. There is concern amongst many scientists for prion disease (neurodegenerative brain disease).

Traditional vaccines do not pass through the blood-brain barrier. Crossing the blood-brain barrier places patients at risk of chronic inflammation and thrombosis (clotting) in the neurological system, contributing to tremors, chronic lethargy, stroke, Bell's Palsy and ALS-type symptoms. The lipid nanoparticles can potentially <u>fuse</u> with brain cells, resulting in delayed neuro-degenerative disease. And the mRNA-induced spike protein can<u>bind</u> to brain

tissue 10 to 20 times stronger than the spike proteins that are (naturally) part of the original virus.

3. Can the unvaccinated get sick from contact with the vaccinated?

The vaccine produces many trillions of particles of spike proteins in the recipient. Patients who are vaccinated can <u>shed</u> some of these (spike protein) particles to close contacts. The particles have the ability to create inflammation and disease in these contacts. In other words, the spike proteins are pathogenic ("disease causing") just like the full virus. What is most worrisome is that a person's body is being suddenly flooded with 13 trillion of these particles and the spike proteins bind *more* tightly than the fully intact virus. Because of the biomimicry (similarity) on the spike, shedding appears to be causing wide variety of autoimmune disease (where the body attacks its own tissue) in some persons. Worldwide cases of pericarditis, shingles, pneumonia, blood clots in the extremities and brain, Bell's Palsy, vaginal bleeding and miscarriages have been reported in persons who are near persons who have been vaccinated. In addition, we know the spike proteins can cross the blood brain barrier, unlike traditional vaccines.

4. What about interaction between unvaccinated children and vaccinated adults?

AFLDS is concerned that some children will become COVID symptomatic after their parents and teachers get vaccinated. This concern does not relate to risk from infection. Indeed, according to the American Academy of Pediatrics and the Children's Hospital Association, approximately "1.6% of children with a known case of COVID-19 have been hospitalized and 0.01% have died." Rather, public health bureaucrats might use these cases of breakthrough transmission or symptoms to speculate that a child's illness is related to a SARS-CoV-2 "variant," when in reality it is a reaction to the vaccine. Our other concern is that children could develop long-term chronic autoimmune disease including neurological problems due to the fact that children have decades ahead of them and trillions of the spike proteins mentioned above.

5. Is there a post-vaccination menstrual bleeding risk?

AFLDS is aware of thousands of <u>reports</u> involving vaginal bleeding, post-menopausal vaginal bleeding, and miscarriages following COVID-19 vaccination as well as anecdotal reports of similar adverse events among those in close contact with the vaccinated. We cannot comment definitively on the close contacts yet, other than to say we have heard reports of this worldwide. But there is so much reporting of vaginal bleeding post-vaccination that it is clear a connection between the vaccine and irregular bleeding exists. Despite this clear-cut evidence, menstrual-cycle changes were not listed among the FDA's <u>common side effects</u> in its phase-three clinical participants. Women's reproductive health needs to be taken seriously rather than <u>waved away</u> by agenda-driven public health officials.

Conclusion

The continued rollout of COVID-19 vaccines moves along without due consideration of patient side effects and post-inoculation complications. AFLDS calls on state and federal health regulators to release more adverse-event-related data and conduct additional follow-up studies before the FDA fully licenses any of the vaccines currently administered under emergency use authorization. The growing body of evidence is too compelling to ignore.

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is <u>America's Frontline Doctors</u> Copyright © <u>Dain Pascocello</u>, <u>America's Frontline Doctors</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Dain Pascocello

*

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca